Patent: 9,161,988
✉ Email this page to a colleague
Summary for Patent: 9,161,988
Title: | Multimeric peptide conjugates and uses thereof |
Abstract: | The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases. |
Inventor(s): | Castaigne; Jean-Paul (Mont-Royal, CA), Demeule; Michel (Beaconsfield, CA), Che; Christian (Longueuil, CA), Thiot; Carine (Montreal, CA), Gagnon; Catherine (Montreal-Nord, CA), Lawrence; Betty (Bolton, CA) |
Assignee: | Angiochem Inc. (Montreal, CA) |
Application Number: | 13/382,069 |
Patent Claims: | see list of patent claims |
Details for Patent 9,161,988
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2029-07-02 |
Merck Teknika Llc | TICE BCG | bcg live | For Injection | 102821 | 06/21/1989 | ⤷ Try a Trial | 2029-07-02 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2029-07-02 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2029-07-02 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2029-07-02 | |
Amgen, Inc. | EPOGEN/PROCRIT | epoetin alfa | Injection | 103234 | 06/01/1989 | ⤷ Try a Trial | 2029-07-02 |
Amgen, Inc. | EPOGEN/PROCRIT | epoetin alfa | Injection | 103234 | ⤷ Try a Trial | 2029-07-02 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |